原发性中枢神经系统淋巴瘤的新型药物:证据与展望
本文系统综述了新型药物在原发性中枢神经系统淋巴瘤(PCNSL)中的现有临床证据并总结在研研究。证据仍限于非对照研究,布鲁顿激酶抑制(如伊布替尼)与免疫调节治疗(如来那度胺)最具前景;靶向雷帕霉素通路未见有意义的临床获益,纳武利尤单抗检查点抑制的证据仅限个例。未来需开展比较性试验。
要点
- PCNSL新型药物证据限于非对照研究,最具前景为伊布替尼布鲁顿激酶抑制与来那度胺等免疫调节治疗。
- 靶向雷帕霉素通路未见有意义的临床获益,纳武利尤单抗检查点抑制证据仅限个例。
- 未来研究应纳入诱导与维持治疗概念及不同机制药物联合,并按分子分型与复发模式选择患者。
核心结论
- PCNSL新型药物证据仍限于非对照研究,最具前景的方法包括伊布替尼布鲁顿激酶抑制与来那度胺等免疫调节治疗。
- 靶向雷帕霉素通路未见有意义的临床获益,纳武利尤单抗检查点抑制的证据仅限个例。
- 需开展比较性试验以改善PCNSL患者预后,未来研究应纳入诱导与维持治疗及不同机制药物联合。
研究设计与样本
- 本文为系统综述,系统回顾新型药物治疗PCNSL的现有临床证据、总结在研研究并讨论前景。
- 高剂量甲氨蝶呤为基础的免疫化疗虽可获得高缓解率,但至少三分之一患者仍面临复发和相关死亡风险。
主要发现
- 新型药物治疗PCNSL的证据体仍限于非对照研究。
- 布鲁顿激酶抑制(伊布替尼)与免疫调节治疗(如来那度胺)为最具前景的方法。
- 靶向雷帕霉素通路未见有意义的临床获益。
- 纳武利尤单抗检查点抑制的证据仅限个例报道。
临床怎么用
- 作者认为未来研究应纳入诱导与维持治疗概念以及不同机制药物的联合。
- 作者认为应根据分子分型和复发模式选择患者,为未来比较性试验提供依据。
- 作者认为亟需开展比较性试验以改善PCNSL患者预后。
局限性
- 新型药物的证据体仍限于非对照研究。
- 靶向雷帕霉素通路未见有意义的临床获益。
- 纳武利尤单抗检查点抑制的证据仅限个例报道。
- 亟需开展比较性试验以改善PCNSL患者预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary central nervous system lymphoma (PCNSL) is a rare aggressive extranodal non- Hodgkin lymphoma. Although high remission rates can be achieved with high-dose methotrexate-based immunochemotherapy, risk of relapse and associated death is still substantial in at least a third of patients. Novel agents for treating lymphoid malignancies have substantially enriched treatment options for PCNSL. We herein systematically review the existing clinical evidence of novel agents in treatment of PCNSL, summarize ongoing studies, and discuss perspectives. The body of evidence for novel agents is still limited to noncomparative studies, but the most promising approaches include Bruton kinase inhibition with ibrutinib and immunomodulatory treatment (eg, with lenalidomide). Targeting the mammalian target of rapamycin pathway does not seem to have a meaningful clinical benefit, and evidence of checkpoint inhibition with nivolumab is limited to anecdotal evidence. Future studies should embrace the concept of induction and maintenance therapy as well as the combination of drugs with different mechanisms of action. Selection of patients based on molecular profiling and relapse patterns should be another aspect informing future comparative trials, which are urgently needed to improve prognosis for patients with PCNSL.
引用
- Illerhaus G, Schorb E, Kasenda B, et al. Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood. 2018. PMID: 29986908. doi:10.1182/blood-2018-01-791558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。